UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 23.

Renner, T J; Nguyen, T T; Romanos, M; Walitza, S; Röser, C; Reif, A; Schäfer, H; Warnke, A; Gerlach, M; Lesch, K P (2011). No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample. ADHD Attention Deficit and Hyperactivity Disorders, 3(3):285-289.

Taurines, R; Grünblatt, E; Schwenck, C; Schecklmann, M; Albantakis, L; Reefschläger, L; Walitza, S; Renner, T; Gerlach, M; Thome, J; Romanos, M (2011). Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder. World Journal of Biological Psychiatry, 12(S1):104-108.

Grünblatt, E; Schmidt, W J; Scheller, D K A; Riederer, P; Gerlach, M (2011). Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. Journal of Neural Transmission, 118(12):1717-1725.

Walitza, S; Kämpf, K; Gnana Oli, R; Warnke, A; Gerlach, M; Stopper, H (2010). Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicology Letters, 193(1):4-8.

Mehler-Wex, C; Walitza, S; Remschmidt, H; Gerlach, M (2010). Editorial. To Andreas Warnke, Professor of Child and Adolescent Psychiatry, Head of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Wuerzburg, Germany, to celebrate his professional life and work at the occasion of his 65th anniversary. ADHD Attention Deficit and Hyperactivity Disorders, 2(4):159-160.

Bartl, J; Link, P; Schlosser, C; Gerlach, M; Schmitt, A; Walitza, S; Riederer, P; Grünblatt, E (2010). Effects of methylphenidate: the cellular point of view. ADHD Attention Deficit and Hyperactivity Disorders, 2(4):225-232.

Oli, R G; Fazeli, G; Kuhn, W; Walitza, S; Gerlach, M; Stopper, H (2010). No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study. Journal of Neural Transmission, 117(6):737-746.

Stopper, H; Schupp, N; Fazeli, G; Dietel, B; Queisser, N; Walitza, S; Gerlach, M (2009). Genotoxicity of the neurotransmitter dopamine in vitro. Toxicology in vitro, 23(4):640-646.

Neuro-Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie. Edited by: Gerlach, M; Mehler-Wex, C; Walitza, S; Warnke, A; Wewetzer, C (2009). Wien: Springer.

Wiesbeck, G; Stohler, R (2009). Alkohol-bezogene Störungen. In: Gerlach, M; Warnke, A; Wewetzer, C. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien: Springer, 345-352.

Stohler, R; Wiesbeck, G (2009). Drogen-(Substanz-)bezogene Störungen. In: Gerlach, M; Warnke, A; Wewetzer, C. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien: Springer, 405-414.

Walitza, S; Kämpf, K; Artamonov, N; Romanos, M; Gnana, O; Wirth, S; Warnke, A; Gerlach, M; Stopper, H (2009). No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicology Letters, 184(1):38-43.

Walitza, S; Romanos, M; Warnke, A (2009). Aufmerksamkeits-Defizit-Hyperaktivitäts-Störungen. In: Gerlach, M; Mehler-Wex, C; Walitza, S; Warnke, A; Wewetzer, C. Neuro-Psychopharmaka im Kindes- und Jugendalter. Wien: Springer, 365-382.

Walitza, S; Halbach, A; Warnke, A (2009). Dokumentierte Patientenaufklärung. Basisinformation zum Aufklärungsgespräch. Behandlung mit Methylphenidat. In: Gerlach, M; Mehler-Wex, C; Walitza, S; Warnke, A; Wewetzer, C. Neuro-Psychopharmaka im Kindes- und Jugendalter. Wien: Springer, 519-22.

Walitza, S; Romanos, M; Seifert, J; Warnke, A; Mehler-Wex, C (2009). Psychostimulanzien. In: Gerlach, M; Warnke, A; Mehler-Wex, C; Walitza, S; Wewetzer, S. Neuro-Psychopharmaka im Kindes- und Jugendalter. Wien: Springer, 289-318.

Walitza, S; Warnke, A; Romanos, M; Gerlach, M; Stopper, H (2009). Wirkt Methylphenidat bei Kindern mit ADHS zytogen? In: Rösler, M; von Gontard, A; Retz, W; Freitag, C M. Diagnose und Therapie der ADHS - Kinder - Jugendliche - Erwachsene. Stuttgart: Kohlhammer, 112.

Wewetzer, C; Walitza, S (2009). Zwangsstörungen im Kindes- und Jugendalter. In: Gerlach, M; Mehler-Wex, C; Walitza, S; Warnke, A; Wewetzer, C. Neuro-Psychopharmaka im Kindes- und Jugendalter. Wien: Springer, 507-512.

Walitza, S; Scherag, A; Renner, T J; Hinney, A; Remschmidt, H; Herpertz-Dahlmann, B; Schulze, E D; Schafer, H; Lange, K W; Wewetzer, C; Gerlach, M (2008). Transmission disequilibrium studies in early onset of obsessive-compulsive disorder for polymorphisms in genes of the dopaminergic system. Journal of Neural Transmission, 115(7):1071-1078.

Renner, T J; Walitza, S; Dempfle, A; Eckert, L; Romanos, M; Gerlach, M; Schäfer, H; Warnke, A; Lesch, K P; Jacob, C (2008). Allelic variants of SNAP25 in a family-based sample of ADHD. Journal of Neural Transmission, 115(2):317-321.

Stopper, H; Walitza, S; Warnke, A; Gerlach, M (2008). Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. Journal of Neural Transmission, 115(2):331-334.

Gerlach, M; Wewetzer, C; Fleischhaker, C; Mehler-Wex, C; Schulz, E; Seifert, J; Walitza, S; Warnke, A (2008). Entwicklungspsychopharmakologie. In: Herpertz-Dahlmann, B; Resch, F; Schulte Markwort, M; Warnke, A. Entwicklungspsychiatrie. Stuttgart: Schattauer, 372-407.

Milosevic, J; Maisel, M; Wegner, F; Leuchtenberger, J; Wenger, R H; Gerlach, M; Storch, A; Schwarz, J (2007). Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. Journal of Neuroscience, 27(2):412-421.

Roessner, V; Walitza, S; Riederer, F; Hünnerkopf, R; Rothenberger, A; Gerlach, M; Moser, A (2007). Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD? Behavioral and Brain Functions, 3 : 64:1-6.

This list was generated on Sun Jul 23 14:42:48 2017 CEST.